Clinical Trials

Text Size A A

E-Mail to a Friend






secret  Click to Play Audio


SCCA Clinical Studies: Lung Cancer

 

ABRAXANE® (Nab-Paclitaxel) for Advanced NSCLC (7755)
A Phase II Study of Weekly ABRAXANE® (Nab-Paclitaxel) for Patients with Advanced NSCLC with EGFR Mutations Following Front-Line Therapy with EGFR Tyrosine Kinase Inhibitors

Investigator: Christina Baik;   Conditions: Lung Cancer;    Status: Recruiting;   Study ID: NCT01620190

Radiation Therapy + Cisplatin & Etoposide for Inoperable NSCLC (7506)
A Phase I dose-intensification study using radiation therapy and concurrent cisplatin and etoposide for patients with inoperable non-small cell lung cancer

Investigator: Shilpen Patel, MD;   Conditions: Lung Cancer; Solid Tumors;    Status: Recruiting;   Study ID: NCT01411098

SPECT/CT in Measuring Lung Function in Patients With Lung Cancer Undergoing Radiation Therapy (8180)
Pulmonary Functional Imaging for Radiation Treatment Planning for Lung Cancer

Investigator: Jing Zeng;   Conditions: Lung Cancer;    Status: Recruiting;   Study ID: NCT01982123

Safety and Tolerability of Nivolumab (BMS-936558) for Non-small Cell Lung Cancer (UW11037)
A Multi-arm Phase I Safety Study of Nivolumab in Combination with Gemcitabine/Cisplatin, Pemetrexed/Cisplatin, Carboplatin/Paclitaxel, Bevacizumab maintenance, Erlotinib, Ipilimumab or monotherapy in First line or in Switch Maintenance in Subjects with Stage IIIB/IV Non-small Cell Lung Cancer (NSCLC)

Investigator: Laura Q.M. Chow, MD;   Conditions: Non-small Cell Lung Cancer;    Status: Recruiting;   Study ID: NCT01454102

Proton Beam Radiation Therapy for Recurrent Thoracic Cancer (9148)
Definitive Re-Irradiation with Proton Beam Radiotherapy for Patients with Recurrent Thoracic Cancers

Investigator: Jing Zeng;   Conditions: Lung Cancer;    Status: Recruiting;   Study ID: NCT02204761

Trastuzumab Emtansine for HER2 IHC-Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer (20142268)
A Phase II, Multicenter, Single-Arm Study of Trastuzumab Emtansine in Patients with HER2 IHC-Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Received at Least One Prior Chemotherapy Regimen

Investigator: Christina Baik;   Conditions: Lung Cancer;    Status: Recruiting;   Study ID: NCT02289833

MK-3475 (SCH900475)+ Chemotherapy or Immunotherapy for Non-Small Cell Lung Carcinoma (20141233)
A Phase I/II Study of MK-3475 (SCH900475) in Combination with Chemotherapy or Immunotherapy in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Carcinoma

Investigator: Renato Martins, MD, MPH;   Conditions: Lung Cancer;    Status: Recruiting;   Study ID: NCT02039674

PF-06747775 for Advanced EGFRm Non-Small Cell Lung Cancer (20150645)
Phase 1/2 Open-Label Study of PF-06747775 (Epidermal Growth Factor Receptor T790M Inhibitor) in Patients with Advanced Epidermal Growth Factor Receptor Mutant (DEL 19 OR L858R +/- T790M) Non-Small Cell Lung Cancer

Investigator: Renato Martins, MD, MPH;   Conditions: Non-Small Cell Lung Cancer;    Status: Recruiting;   Study ID: NCT02349633

MEDI4736 + Tremelimumab for Advanced Non-Small Cell Lung Cancer (20131955)
A Phase 1b Open-label Study to Evaluate the Safety and Tolerability of MEDI4736, in Combination with Tremelimumab in Subjects with Advanced Non-Small Cell Lung Cancer

Investigator: Sylvia Lee, MD;   Conditions: Lung Cancer;    Status: Recruiting;   Study ID: NCT02000947

BRAF Kinase Inhibitor GSK2118436 for Advanced NSCLC and BRAF Mutations (UW12020)
A Phase II Study of the Selective BRAF Kinase Inhibitor GSK2118436 in Subjects With Advanced Non-small Cell Lung Cancer and BRAF Mutations

Investigator: Renato G. Martins, MD;   Conditions: Advanced Non-small Cell Lung Cancer;    Status: Recruiting;   Study ID: NCT01336634

Alisertib (MLN8237) in Combination With Paclitaxel for Small Cell Lung Cancer (UW14002)
A Randomized, Double-blind, Placebo-controlled, Phase 2 Clinical Trial of Alisertib (MLN8237) in Combination With Paclitaxel Versus Placebo in Combination With Paclitaxel as Second Line Therapy for Small Cell Lung Cancer (SCLC).

Investigator: Christina S. Baik, MD;   Conditions: Small Cell Lung Cancer;    Status: Pending;   Study ID: NCT02038647

LY2875358 + Erlotinib for Non-Small-Cell Lung Cancer (I4C-MC-JTBC)
A Randomized, Open-Label Phase 2 Study Evaluating LY2875358 Plus Erlotinib and LY2875358 Monotherapy in MET Diagnostic Positive NSCLC Patients With Acquired Resistance to Erlotinib

Investigator: Renato G. Martins, MD;   Conditions: Lung Cancer;    Status: Recruiting;   Study ID: NCT01900652

ID-LV305 for Locally Advanced, Relapsed or Metastatic Cancer Expressing NY-ESO-1
A Phase 1 Safety Study of Intradermal ID-LV305 in Patients With Locally Advanced, Relapsed or Metastatic Cancer Expressing NY-ESO-1

Investigator: Seth M. Pollack, MD;   Conditions: Breast Cancer, Melanoma, Non-small Cell Lung Cancer, Ovarian Cancer, Sarcoma;    Status: Recruiting;   Study ID: NCT02122861

Recombinant Interleukin-15 in Treating Patients With Advanced Solid Tumors
A Phase 1 Study of Recombinant Human IL15 (rhIL15) in Adults With Advanced Solid Tumors: Melanoma, Renal Cell, Non-Small Cell Lung and Head and Neck Cancer

Investigator: John A. Thompson, MD;   Conditions: Melanoma, Kidney Cancer, Non-Small Cell Lung Cancer, Head and Neck Cancer;    Status: Recruiting;   Study ID: NCT01727076

MPDL3280A + Cobimetinib for Locally Advanced or Metastatic Cancer
A Phase 1b Study of the Safety and Pharmacology of MPDL3280A Administered With Cobimetinib in Patients With Locally Advanced or Metastatic Solid Tumors

Investigator: Laura Chow, MD;   Conditions: Neoplasms;    Status: Recruiting;   Study ID: NCT01988896

Ruxolitinib in Combination With Pemetrexed/Cisplatin in Non Small Cell Lung Cancer (UW14019)
A Randomized, Double-Blind Phase 2 Study of Ruxolitinib or Placebo in Combination With Pemetrexed/Cisplatin and Pemetrexed Maintenance for Initial Treatment of Subjects With Nonsquamous Non-Small Cell Lung Cancer That Is Stage IIIB, Stage IV, or Recurrent

Investigator: Laura Chow, MD;   Conditions: Non-Small-Cell Lung Cancer;    Status: Recruiting;   Study ID: NCT02119650

Oral MGCD265 for Advanced Cancer (UW13036)
Open-Label Dose-Escalation Trial to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Daily Oral MGCD265 Administered Without Interruption to Subjects With Advanced Malignancies

Investigator: Keith Eaton, MD;   Conditions: Advanced Cancer;    Status: Recruiting;   Study ID: NCT00697632

CO-1686 vs. Erlotinib for Non-Small Cell Lung Cancer (UW14055)
TIGER 1: A Randomized, Open-Label, Phase 2 Study of CO-1686 or Erlotinib as First-Line Treatment of Patients With EGFR-Mutant Advanced NSCLC

Investigator: ;   Conditions: Non-Small Cell Lung Cancer;    Status: Recruiting;   Study ID: NCT02186301

Photon Therapy Vs. Proton Therapy for Non-small Cell Lung Cancer (RTOG 1308)
Phase III Randomized Trial Comparing Overall Survival After Photon Versus Proton Chemoradiotherapy for Inoperable Stage II-IIIB NSCLC

Investigator: Ramesh Rengan, MD;   Conditions: Non-small Cell Lung Cancer;    Status: Recruiting;   Study ID: NCT01993810

Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer
Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)

Investigator: Renato G. Martins, MD;   Conditions: Lung Cancer;    Status: Pending;   Study ID: NCT02194738

Erlotinib Hydrochloride for Stage IB-IIIA NSCLC That Has Been Completely Removed by Surgery (Alliance A081105l)
Randomized Double Blind Placebo Controlled Study of Erlotinib or Placebo in Patients With Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-small Cell Lung Cancer (NSCLC)

Investigator: Renato G. Martins, MD;   Conditions: Lung Cancer;    Status: Pending;   Study ID: NCT02193282

Expanded Access Study of Alectinib for Non-Small Cell Lung Cancer
An Open Label, Multicenter, Single-Arm, Expanded Access Study of Alectinib for Patients With ALK-Rearranged Non-Small Cell Lung Cancer After Disease Progression on or Intolerance to Prior ALK Tyrosine Kinase Inhibitor Therapy

Investigator: Christina S. Baik, MD;   Conditions: Squamous Non-Small Cell Lung Cancer;    Status: Recruiting;   Study ID: NCT02271139